Skip to main content

GNS Partners with NCI on Personalized Treatment of NSCLC

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Healthcare IT firm GNS Healthcare is collaborating with the National Cancer Institute to help determine what treatments may work best for individuals with non-small cell lung cancer.

Under the deal announced this week, GNS will use its REFS platform to create computer models of NSCLC in a hypothesis-free, unbiased manner that will be simulated to identify key molecular mechanisms of the disease. Ultimately, the partners hope to identify biomarkers and biological mechanisms that can help guide treatments for NSCLC patients, as well as result in more effective new drugs.

The REFS platform is comprised of integrated machine learning algorithms and software that extract "causal" relationships from complex data "to explore novel unseen conditions and predictions forward in time," the Cambridge, Mass.-based company said.

GNS will analyze data from the laboratory of Terry van Dyke, director of the Center for Advanced Preclinical Research at NCI. The data was generated from genetically modified mouse models of NSCLC.

Financial and other terms of the partnership were not disclosed.

Earlier this year, GNS and NCI said they were partnering to analyze the institute's NCI-60 cancer cell line panel for pharmacogenomic purposes.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.